Search for: "ACTAVIS-ELIZABETH, L.L.C." Results 1 - 12 of 12
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Dec 2010, 8:19 am by CivPro Blogger
The cases, which the Court consolidated, are Actavis Elizabeth, L.L.C. v. [read post]
26 Mar 2011, 10:00 pm by Adam Schlossman
Demahy (09-1501) and Actavis Elizabeth, L.L.C. v. [read post]
3 Aug 2009, 7:29 am
All responding defendants (Actavis, Inc.; Actavis-Elizabeth, L.L.C.; Barr Pharmaceuticals, Inc.; Baxter Healthcare Corp.; Duramed Pharmaceuticals, Inc.; Pliva, Inc.; Pliva USA, Inc.; Schwarz Pharma, Inc.; Teva Pharmaceuticals USA, Inc.; and Wyeth) opposed centralization, as did one Plaintiff from Vermont. [read post]
5 Jun 2011, 1:12 pm by Josh Blackman
Mensing Reverse Details Actavis Elizabeth, L.L.C. v. [read post]
10 Dec 2010, 2:54 pm by Anna Christensen
Mensing (Granted )Docket: 09-993Issue(s): Whether the Eighth Circuit abrogated the Hatch-Waxman Amendments by allowing state tort liability for failure to warn in direct contravention of the Act’s requirement that a generic drug’s labeling be the same as the labeling approved by the Food and Drug Administration for the listed (or branded) drug.Certiorari-Stage Documents:Opinion below (8th Circuit)Petition for certiorariBrief in oppositionSupplemental brief of petitionersPetitioners'… [read post]
9 Dec 2010, 1:10 pm by Christa Culver
Mensing (Granted )Docket: 09-993Issue(s): Whether the Eighth Circuit abrogated the Hatch-Waxman Amendments by allowing state tort liability for failure to warn in direct contravention of the Act’s requirement that a generic drug’s labeling be the same as the labeling approved by the Food and Drug Administration for the listed (or branded) drug.Certiorari-Stage Documents:Opinion below (8th Circuit)Petition for certiorariBrief in oppositionSupplemental brief of petitionersPetitioners'… [read post]
1 Dec 2010, 5:54 pm by Christa Culver
MensingDocket: 09-993Issue(s): Whether the Eighth Circuit abrogated the Hatch-Waxman Amendments by allowing state tort liability for failure to warn in direct contravention of the Act’s requirement that a generic drug’s labeling be the same as the labeling approved by the Food and Drug Administration for the listed (or branded) drug.Certiorari-Stage Documents:Opinion below (8th Circuit)Petition for certiorariBrief in oppositionSupplemental brief of petitionersPetitioners'… [read post]